mRNA Galsomes Vaccine Protects Budgerigars Against Virulent Challenge.

Background/objectives: is an avian respiratory pathogen that regularly infects budgerigars () and is a known zoonosis. This study aimed to evaluate the efficacy of a nucleoside-modified mRNA vaccine formulated in lipid nanoparticles (LNPs), either with (mRNA Galsomes) or without (mRNA LNPs) the glycolipid antigen α-Galactosylceramide, in protecting budgerigars against genotype A infection.

Methods: Three groups of eight budgerigars received two intramuscular vaccinations with PBS, mRNA LNPs or mRNA Galsomes, and were subsequently challenged via aerosol with the genotype A strain 90/1051.